Ruomu Li

Partner
[email protected]
查阅中文
Full contact info

About Ruomu

Ruomu focuses her practice on complex mergers & acquisitions, private equity transactions and venture capital investments. She has over 17 years of experience in a broad range of transactions in the life sciences and technology industries, including buy-side and sell-side public and private mergers, going private transactions, de-SPAC transactions, stock and asset acquisitions, divestitures, spinoffs, join ventures and minority investments.

View full bio

Experience

Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement

Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement

November 18, 2024

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Read more

Related contacts

Mark Ballantyne
Partner, Reston
Kenneth Krisko
Partner, Reston
Brian Leaf
Partner, Reston
J. Brian Stalter
Special Counsel, New York
Ruomu Li
Partner, Shanghai
David Brinton
Associate, Washington, DC
Arjan Ganji
Associate, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Daniel I. Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Francis Wheeler
Partner, Colorado
Rebecca Ross
Special Counsel, Washington, DC
John Forrest
Associate, Boston
Zack Gong
Associate, Shanghai
Michael Shen
Counsel, Shanghai
Robin K. Lee
Paralegal Specialist, Colorado

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Mergers and Acquisitions
Public Companies
Capital Markets
Life Sciences and Healthcare Regulatory
CooleyREG
Tax

ProfoundBio Announces $1.8 Billion Acquisition by Genmab

ProfoundBio Announces $1.8 Billion Acquisition by Genmab

April 3, 2024

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Rowook Park
Partner, San Diego
Ruomu Li
Partner, Shanghai
Jenny Ge
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Jamie Leigh
Partner, San Francisco
Izzy Lubarsky
Partner, New York
Barbara Mirza
Partner, Santa Monica
Sonia Nath
Partner, Washington, DC
Jean Park
Partner, New York
Lei Shen
Partner, Chicago
Stacey A. Bradford
Special Counsel, Washington, DC
Jeff Goldman
Special Counsel, Palo Alto
Amy Hallman Rice
Special Counsel, San Diego
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Andrew Bae
Associate, Washington, DC
Julia R. Brinton
Associate, Washington, DC
Megan Drill
Associate, San Diego
Mari Dugas
Associate, Washington, DC
Allison Kutner
Associate, New York
Jiqiang Lin
Associate, New York
Tyler Saavedra-Buckley
Associate, San Francisco
Ivy Wang
Associate, Shanghai
Monica Xu
Counsel, Shanghai
Freddy Yip
Associate, Hong Kong
Zhijing Yu
Associate, Singapore
Andy Zachrich
Associate, San Diego
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

Mergers and Acquisitions
Biotechnology
Healthcare
Life Sciences
Life Sciences and Healthcare Regulatory
Life Sciences Corporate Partnering and Licensing
Asia
Emerging Companies
Tax
Cyber/Data/Privacy
Compensation and Benefits
Labor and Employment
Antitrust and Competition
CFIUS

SJ Semiconductor Signs $340 Million Series C+ Financing

SJ Semiconductor Signs $340 Million Series C+ Financing

April 12, 2023

Cooley advised SJ Semiconductor Corporation (SJSemi), a semiconductor foundry, on its $340 million Series C+ financing, with a post-money valuation of close to US$2 billion.

Related contacts

Ruomu Li
Partner, Shanghai
Wenlan Geng
Associate, Shanghai
Zixiang Liu
Associate, Shanghai

Related Practices & Industries

Private Equity
Venture Capital
Semiconductor
Mergers and Acquisitions
Emerging Companies
Asia

Admissions and credentials

California

New York

Rankings and accolades

Legal 500 Asia Pacific

  • Corporate and M&A in China – Leading Individual (2022-2024), Recommended Lawyer (2020-2021)
  • Private Equity in China – Next Generation Partner (2021-2024)
  • Life Sciences and Healthcare in China – Next Generation Partner (2022-2024) 
  • Real Estate and Constructions in China – Recommended Lawyer (2021)
  • Corporate (including M&A) in Hong Kong – Recommended Lawyer (2022)
  • Private Equity in Hong Kong – Recommended Lawyer (2022)

Chambers and Partners Greater China

  • Private Equity: Buyouts and Venture Investment – Ranked Lawyer (2021-2023)
  • Corporate and M&A – Ranked Lawyer (2023) 

IFLR1000 Asia Pacific Rankings

  • M&A in China  – Highly Regarded Lawyer (2022-2023)
  • Private Equity in China – Highly Regarded Lawyer (2022-2023)

IFLR1000 Women Leaders Award (2022-2023)